Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:58:05.294Z.
Calculation as of: 2026-10-06T19:58:05.294Z.
Quote observation: 2026-10-06T19:55:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$212.65M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.94M
PS Ratio
7886.77
TTM Avg
10075.42
3Y Avg
5826.11
5Y Avg
3526.58
Market Cap
$209.68M
PS Ratio
44.75
TTM Avg
28.94
3Y Avg
12.07
5Y Avg
12.54
Market Cap
$215.58M
PS Ratio
9.61
TTM Avg
19.23
3Y Avg
17.60
5Y Avg
17.60
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $212.65M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 1.64 | 3.22 | 3.89 | 3.24 |
| Sionna Therapeutics, Inc. (SION)vs › | $211.53M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.38M | 2.84 | 9.59 | 7.89 | 14.57 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | 7886.77 | 10075.42 | 5826.11 | 3526.58 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.68M | 44.75 | 28.94 | 12.07 | 12.54 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.58M | 9.61 | 19.23 | 17.60 | 17.60 |
| Pro-Dex, Inc. (PDEX)vs › | $208.44M | 2.69 | 2.27 | 2.02 | 1.85 |
| Electra Therapeutics Inc. (ETRA)vs › | $206.72M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.95M | N/A | 9.28 | 5.99 | 38.18 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
